The partnership will bring Royal Biologics’ products to more patients in the U.S., including the Fibrinet platelet rich fibrin matrix for spinal fusions and the Maxx-PRP for orthopedics.
The partnership will also seek adoption of the biologics in the VA and department of defense.
